Rising Hormonal Disease Prevalence Powers Growth In The Acromegaly Market: Key Factor Driving The Growth In The Acromegaly Market

The Acromegaly Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Expected Acromegaly Market Size During the Forecast Period?
The market size for acromegaly has experienced swift expansion in the latest years. It is projected to rise from $2.15 billion in 2024 to $2.57 billion in 2025, reflecting a compound annual growth rate (CAGR) of 19.6%. The substantial growth observed during the historical period can be credited to factors such as the rising incidences of acromegaly therapeutics, an increased public awareness about the condition, initiatives taken by the government, and a high demand for efficient treatments.

The market for acromegaly is predicted to experience considerable expansion in the coming few years. It is forecasted to escalate to $4.92 billion in 2029 with a compound annual growth rate (CAGR) of 17.6%. The surge during the forecast period can be ascribed to funds being directed towards research and development for treatments of acromegaly, a rise in health screenings, increased healthcare expenditures, and a growing preference for minimally invasive treatment alternatives. The anticipated period will see key trends such as breakthrough treatments for acromegaly, the creation of targeted therapies, a robust drug pipeline, advancements in treatment methodologies, and progress in personalized medicine.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12913

What Are the High-Growth Segments in the Acromegaly Market?
The acromegaly market covered in this report is segmented -

1) By Type: Ectopic Acromegaly, Acromegaly Due To Growth Hormone
2) By Diagnosis: GH And IGF-I Measurement, Growth Hormone Suppression Test, Imaging, Other Diagnosis
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
4) By Treatment: Medication, Somatostatin analogues, Dopamine Agonists, Growth Hormone Antagonist, Surgery, Radiation, Other Treatments
5) By End Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:
1) By Ectopic Acromegaly: Tumor-Induced Ectopic Acromegaly, Non-Tumor-Induced Ectopic Acromegaly
2) By Acromegaly Due To Growth Hormone: Primary Growth Hormone Excess, Secondary Growth Hormone Excess

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12913&type=smp

What Key Drivers Are Expected to Influence Future Acromegaly Market Growth?
As the incidence of hormonal ailments like diabetes continues to rise, the acromegaly market is projected to experience robust growth. These hormonal disorders, also known as endocrine disorders, arise from a malfunctioning endocrine system and diabetes is among the most common of these. Diseases such as acromegaly can occur due to an overproduction of certain hormones such as the growth hormone or cortisol. Moreover, around half of the people with acromegaly might develop insulin resistance or type 2 diabetes as high levels of growth hormones adversely affect insulin synthesis. In fact, between March 2022 and March 2023, according to the Office for Health Improvement and Disparities, the share of type 1 diabetes patients receiving the eight recommended care processes rose by 22%. For type 2 diabetes, the increase was 21%. The achievement of desired HbA1c levels saw a record rise to 37.9%, as per the National Diabetes Audit. Hence, the surge in hormonal diseases is fueling the acromegaly market's expansion.

Acromegaly Market Driver: The Influence of Genetic Aberrations on the Growth of the Acromegaly Market The acromegaly market's growth is projected to be driven by the rising incidence of genetic anomalies. Technically known as genetic defects or disorders, such abnormalities arise from changes or mutations in the DNA sequence of a person's genes, leading to atypical attributes, functions, or traits. Acromegaly is often a result of overproduction of the growth hormone (GH) by the pituitary gland, typically due to benign adenomas, which can occur sporadically or be associated with certain genetic abnormalities. For instance, the World Health Organization disclosed in February 2022 that each year, birth defects lead to the death of 240,000 newborns in the first 28 days of life and an additional 170,000 casualties among children between one month and five years of age, including those from heart defects, neural tube defects, and Down syndrome. Therefore, the increasing prevalence of genetic anomalies is propelling the acromegaly market forward.

Which Companies Hold the Largest Share Across Different Acromegaly Market Segments?
Major companies operating in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc, Strongbridge Biopharma PLC, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.

What Trends Are Driving Growth in The Acromegaly Market?
Primary players in the acromegaly market are striving to create original products and solutions, such as generic lanreotide, in order to broaden treatment alternatives and ameliorate patient outcomes. Generic lanreotide is a non-proprietary version of the drug used to tackle acromegaly and specific neuroendocrine tumors. This substance functions as a somatostatin analogue, limiting the secretion of growth hormones and increasing access to effective therapeutic solutions for patients. For example, Teva Pharmaceutical Industries Ltd., a pharmaceutical company based in Israel with a focus on generic drugs, introduced the first and only generic variant of Sandostatin LAR Depot within the United States in October 2024. The injectable suspension known as octreotide acetate is used for the treatment of acromegaly and acute diarrhea associated with carcinoid syndrome. This novel introduction improves the accessibility to essential therapy for patients in need of these treatments.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/acromegaly-global-market-report

What Are the Emerging Geographies for The Acromegaly Market Growth?
North America was the largest region in the acromegaly market in 2024. The regions covered in acromegaly market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Acromegaly Market?
2. What is the CAGR expected in the Acromegaly Market?
3. What Are the Key Innovations Transforming the Acromegaly Industry?
4. Which Region Is Leading the Acromegaly Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.